Laurent Pharmaceuticals is a private orphan drug company developing a first-in-class oral therapy with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. Laurent has a clinical stage drug development program (LAU-7b) addressing the compromised immuno-inflammatory response in Cystic Fibrosis (CF), a critical but still enigmatic pathogenic pathway leading to pulmonary insufficiency in CF patients.